Sana Biotechnology Inc - Asset Resilience Ratio
Sana Biotechnology Inc (SANA) has an Asset Resilience Ratio of 4.64% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Sana Biotechnology Inc's Asset Resilience Ratio has changed over time. Check SANA strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Sana Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SANA market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $17.34 Million | 4.64% |
| Total Liquid Assets | $17.34 Million | 4.64% |
Asset Resilience Insights
- Limited Liquidity: Sana Biotechnology Inc maintains only 4.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sana Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Sana Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Sana Biotechnology Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Sana Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 15.95% | $66.51 Million | $416.89 Million | +10.98pp |
| 2024-12-31 | 4.98% | $24.93 Million | $501.02 Million | -7.70pp |
| 2023-12-31 | 12.68% | $71.68 Million | $565.30 Million | -17.37pp |
| 2022-12-31 | 30.05% | $247.20 Million | $822.72 Million | +3.66pp |
| 2021-12-31 | 26.38% | $297.97 Million | $1.13 Billion | -8.32pp |
| 2020-12-31 | 34.71% | $253.46 Million | $730.30 Million | +20.51pp |
| 2019-12-31 | 14.20% | $58.95 Million | $415.19 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $34.33 Million | -- |
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more